Search
Astria Therapeutics Inc
ATXSAdd to Watchlist
12.580USD
0.0000.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
718.13MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-01-22The current earnings forecast score of Astria Therapeutics Inc is 6.25, ranking 342 out of 395 in the Biotechnology & Medical Research industry. The average price target is 13.00, with a high of 35.00 and a low of 13.00.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
13.000
Target Price
+3.34%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Astria Therapeutics Inc
ATXS
3
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Astria Therapeutics Inc's price target?
Analysts forecast that Astria Therapeutics Inc's price target is USD 13.00, with the highest forecast at USD 35.00 and the lowest forecast at USD 13.00.
How have Astria Therapeutics IncATXS's recent earnings per share performed?
The market expectation was USD -0.55, while Astria Therapeutics IncATXS's earnings per share (EPS) for the previous quarter was USD -0.57. EPS for the next quarter is expected at USD -0.54.
What is the analyst rating for Astria Therapeutics Inc?
Based on the ratings of Astria Therapeutics Inc's stock from 3 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.